Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

被引：0

作者：

M. Lefort

S. Sharmin

J. B. Andersen

S. Vukusic

R. Casey

M. Debouverie

G. Edan

J. Ciron

A. Ruet

J. De Sèze

E. Maillart

H. Zephir

P. Labauge

G. Defer

C. Lebrun-Frenay

T. Moreau

E. Berger

P. Clavelou

J. Pelletier

B. Stankoff

O. Gout

E. Thouvenot

O. Heinzlef

A. Al-Khedr

B. Bourre

O. Casez

P. Cabre

A. Montcuquet

A. Wahab

J. P. Camdessanché

A. Maurousset

H. Ben Nasr

K. Hankiewicz

C. Pottier

N. Maubeuge

D. Dimitri-Boulos

C. Nifle

D. A. Laplaud

D. Horakova

E. K. Havrdova

R. Alroughani

G. Izquierdo

S. Eichau

S. Ozakbas

F. Patti

M. Onofrj

A. Lugaresi

M. Terzi

P. Grammond

F. Grand’Maison

机构：

[1] Univ Rennes,Arènes

[2] EHESP, UMR 6051, RSMS (Recherche sur les Services et Management en Santé)

[3] CNRS, U 1309

[4] Inserm,Department of Medicine

[5] Univ Rennes,Melbourne MS Centre, Department of Neurology

[6] CHU Rennes,Department of Neurology

[7] Investigation Clinique de Rennes)],Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline Et Neuro

[8] University of Melbourne,Inflammation

[9] Royal Melbourne Hospital,Centre Des Neurosciences de Lyon, UMR5292

[10] The Danish Multiple Sclerosis Registry,Centre Hospitalier Régional Universitaire de Nancy

[11] Copenhagen University Hospital,Centre Hospitalier Universitaire de Rennes

[12] Hôpital Neurologique Pierre Wertheimer,Centre Hospitalier Universitaire de Toulouse

[13] Hospices Civils de Lyon,Centre Hospitalier Universitaire de Bordeaux

[14] Observatoire Français de La Sclérose en Plaques,Service des maladies inflammatoires du système nerveux – neurologie, centre d’investigation clinique de Strasbourg

[15] INSERM,Assistance Publique Des Hôpitaux de Paris

[16] Université,Centre Hospitalier Universitaire de Lille

[17] Claude Bernard Lyon 1,Centre Hospitalier Universitaire de Montpellier

[18] Faculté de médecine Lyon Est,Centre Hospitalier Universitaire de Caen Normandie

[19] Eugene Devic EDMUS Foundation,Centre Hospitalier Universitaire de Nice

[20] Hôpital Central,Centre Hospitalier Universitaire Dijon Bourgogne

[21] Hôpital Pontchaillou,Centre Hospitalier Régional Universitaire de Besançon

[22] Hôpital Purpan,Service de Neurologie

[23] CRC-SEP,Assistance Publique Des Hôpitaux de Paris

[24] Hôpital Pellegrin,Centre Hospitalier Universitaire de Martinique

[25] Hôpitaux Universitaire de Strasbourg,Centre Hospitalier Universitaire Limoges

[26] Hôpital de Hautepierre,Assistance Publique Des Hôpitaux de Paris

[27] Hôpital de La Pitié-Salpêtrière,Centre Hospitalier Universitaire de Poitiers

[28] Hôpital Salengro,Assistance Publique Des Hôpitaux de Paris

[29] Hôpital Gui de Chauliac,Centre Hospitalier de Versailles

[30] Hôpital Côte de Nacre,Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine

[31] UR2CA-URRIS,Division of Neurology, Department of Medicine

[32] ,GF Ingrassia Department

[33] Université Nice Côte d’Azur,Department of Neuroscience, Imaging, and Clinical Sciences

[34] Hôpital,Dipartimento Di Scienze Biomediche E Neuromotorie

[35] Hôpital François Mitterrand,Medical Faculty

[36] Maladies Inflammatoires du Système Nerveux Et Neurologie Générale,Nehme and Therese Tohme Multiple Sclerosis Center

[37] Hôpital Jean Minjoz,Department of Basic Medical Sciences, Neuroscience and Sense Organs

[38] Centre Hospitalier Universitaire de Clermont-Ferrand,School of Medicine and Public Health

[39] Hôpital Gabriel-Montpied,Department of Neurology

[40] Aix Marseille Univ,Department of Neuroscience

[41] APHM,Department of Medicine and Surgery

[42] Hôpital de La Timone,Department of Emergency and General Medicine

[43] Hôpital Saint-Antoine,Department of Neurology, Faculty of Medicine

[44] Fondation Adolphe de Rothschild de L’œil Et du Cerveau,Department of Clinical Epidemiology

[45] Centre Hospitalier Universitaire de Nîmes,Danish Multiple Sclerosis Centre, Department of Neurology

[46] Hôpital Carémeau,Department of Neurology

[47] Centre Hospitalier Intercommunal de Poissy Saint-Germain-en-Laye,Department of Neurology

[48] Centre Hospitalier Universitaire d’Amiens Picardie,Department of Clinical Medicine

[49] Rouen University Hospital,Department of Neurology

[50] Centre Hospitalier Universitaire Grenoble-Alpes,Central Clinical School

来源：

BMC Medical Research Methodology | / 22卷

关键词：

Effectiveness; Multiple sclerosis; Propensity score; Indication bias; Causal contrasts; Censoring; Positivity assumption;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis
Spelman, T.
Acosta, C.
Hyde, R.
Campbell, N.
Havrdova, E.
Horakova, D.
Trojano, M.
De Luca, G.
Lugaresi, A.
Izquierdo, G.
Grammond, P.
Duquette, P.
Alroughani, R.
Pucci, E.
Granella, F.
Lechner-Scott, J.
Sola, P.
Ferraro, D.
Grand-Maison, F.
Terzi, M.
Rozsa, C.
Boz, C.
Hupperts, R.
Van der Walt, A.
Van Pesch, V.
Oreja-Guevara, C.
Jokubaitis, V.
Kalincik, T.
Butzkueven, H.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 526 - 527
[32] Comparative Effectiveness of Cladribine versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis: The MERLYN Study
Brownlee, W.
Haghikia, A.
Hayward, B.
Waser, N.
Kayaniyil, S.
Khan, Z.
Duncan, J.
Millar, S.
Harty, G.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 63 - 63
[33] Comparative effectiveness of dimethylfumarate and fingolimod in an Italian monocentric cohort of relapsing remitting multiple sclerosis patients
Moiola, L.
Esposito, F.
Di Cristinzi, M.
Ferre, L.
Signori, A.
Sferruzza, G.
Radaelli, M.
Sangalli, F.
Dalla Costa, G.
Colombo, B.
Boneschi, F. Martinelli
Rocca, M. A.
Martinelli, V.
Filippi, M.
Sormani, M. P.
Comi, G.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 677 - 677
[34] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts
Sharmin, S.
McCombe, P.
Slee, M.
Lechner-Scott, J.
Skibina, O.
Buzzard, K.
van der Walt, A.
Vucic, S.
Butzkueven, H.
Kalincik, T.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (4_SUPPL) : 8 - 9
[35] Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
Sifat Sharmin
Mathilde Lefort
Johanna Balslev Andersen
Emmanuelle Leray
Dana Horakova
Eva Kubala Havrdova
Raed Alroughani
Guillermo Izquierdo
Serkan Ozakbas
Francesco Patti
Marco Onofrj
Alessandra Lugaresi
Murat Terzi
Pierre Grammond
Francois Grand’Maison
Bassem Yamout
Alexandre Prat
Marc Girard
Pierre Duquette
Cavit Boz
Maria Trojano
Pamela McCombe
Mark Slee
Jeannette Lechner-Scott
Recai Turkoglu
Patrizia Sola
Diana Ferraro
Franco Granella
Julie Prevost
Davide Maimone
Olga Skibina
Katherine Buzzard
Anneke Van der Walt
Bart Van Wijmeersch
Tunde Csepany
Daniele Spitaleri
Steve Vucic
Romain Casey
Marc Debouverie
Gilles Edan
Jonathan Ciron
Aurélie Ruet
Jérôme De Sèze
Elisabeth Maillart
Hélène Zephir
Pierre Labauge
Gilles Defer
Christine Lebrun-Frénay
Thibault Moreau
Eric Berger
CNS Drugs, 2021, 35 : 1217 - 1232
[36] Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
Sharmin, Sifat
Lefort, Mathilde
Andersen, Johanna Balslev
Leray, Emmanuelle
Horakova, Dana
Havrdova, Eva Kubala
Alroughani, Raed
Izquierdo, Guillermo
Ozakbas, Serkan
Patti, Francesco
Onofrj, Marco
Lugaresi, Alessandra
Terzi, Murat
Grammond, Pierre
Grand'Maison, Francois
Yamout, Bassem
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Boz, Cavit
Trojano, Maria
McCombe, Pamela
Slee, Mark
Lechner-Scott, Jeannette
Turkoglu, Recai
Sola, Patrizia
Ferraro, Diana
Granella, Franco
Prevost, Julie
Maimone, Davide
Skibina, Olga
Buzzard, Katherine
Van der Walt, Anneke
Van Wijmeersch, Bart
Csepany, Tunde
Spitaleri, Daniele
Vucic, Steve
Casey, Romain
Debouverie, Marc
Edan, Gilles
Ciron, Jonathan
Ruet, Aurelie
De Seze, Jerome
Maillart, Elisabeth
Zephir, Helene
Labauge, Pierre
Defer, Gilles
Lebrun-Frenay, Christine
Moreau, Thibault
Berger, Eric
CNS DRUGS, 2021, 35 (11) : 1217 - 1232
[37] Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
Mehdi Rezaee
Mohammad Hossein Morowvat
Maryam Poursadeghfard
Armin Radgoudarzi
Khosro Keshavarz
BMC Health Services Research, 22
[38] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts
Sharmin, S.
McCombe, P.
Slee, M.
Lechner-Scott, J.
Skibina, O.
Buzzard, K.
van der Walt, A.
Vucic, S.
Butzkueven, H.
Kalincik, T.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 : 8 - 9
[39] Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
Rezaee, Mehdi
Morowvat, Mohammad Hossein
Poursadeghfard, Maryam
Radgoudarzi, Armin
Keshavarz, Khosro
BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
[40] Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab.
Alping, P.
Piehl, F.
Frisell, T.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 36 - 36

← 1 2 3 4 5 →